Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,625 across all filing types
Latest filing 2021-05-25 Proxy Solicitation & In…
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
MAJOR TRANSACTION LIMITED PARTNERSHIP AGREEMENT
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a circular issued by Overseas Chinese Town (Asia) Holdings Limited dated 26 May 2021. It discusses a major transaction involving a Limited Partnership Agreement, providing detailed information about the transaction, parties involved, capital commitments, management structure, and investment objectives. The document is addressed to shareholders and includes a letter from the board, definitions, and appendices with financial information. The content is typical of a circular sent to shareholders to inform them about a significant corporate transaction and to seek their approval or provide detailed disclosure. It is not a full financial report, earnings release, or regulatory filing. It is also not a proxy solicitation or voting results announcement, but rather a detailed explanatory circular about a major transaction. Therefore, the document fits best into the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings related to major transactions.
2021-05-25 English
MAJOR TRANSACTION SUPPLEMENTAL AGREEMENT IN RELATION TO SUBSCRIPTION OF 49% INTEREST IN THE CAYMAN FUND
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a circular from Overseas Chinese Town (Asia) Holdings Limited dated 26 May 2021, concerning a major transaction supplemental agreement related to the subscription of a 49% interest in a Cayman Fund. It includes detailed definitions, a letter from the board, financial information of the group, and general information. The document is lengthy (15,000 characters) and contains substantive information about the transaction, parties involved, and financial details. It is not a brief announcement or a proxy solicitation but a detailed circular providing information to shareholders about a major transaction and related agreements. This type of document fits the category of a Proxy Solicitation & Information Statement (PSI), as it is sent to shareholders to provide information and request votes or approvals related to corporate actions, in this case, a major transaction and supplemental agreement. Therefore, the appropriate classification is PSI with high confidence.
2021-05-25 English
RESULTS OF THE 2020 ANNUAL GENERAL MEETING HELD ON 21 MAY 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the results of the 2020 Annual General Meeting (AGM) held on 21 May 2021. It details the voting outcomes on various resolutions including receipt of audited accounts, re-appointment of auditors, re-election of directors, and share mandates. The document does not contain the full annual report or financial statements but reports on the voting results of the AGM. It references the AGM Notice and Circular but does not include the reports themselves. The document length is about 5939 characters, which is consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2021-05-21 English
GRANT OF WAIVER FROM STRICT COMPLIANCE WITH RULE 14.41(A) OF THE LISTING RULES
Regulatory Filings Classification · 95% confidence The document is an announcement from Overseas Chinese Town (Asia) Holdings Limited regarding the grant of a waiver from strict compliance with a specific listing rule (Rule 14.41(a)) by the Stock Exchange of Hong Kong. It references previous announcements and conditions related to the waiver but does not contain financial statements, detailed financial data, or comprehensive report content. The document is relatively short (2253 characters) and serves to inform shareholders and the public about the waiver granted and related procedural matters. It is not a full report, financial statement, or detailed presentation but an official announcement about a regulatory compliance matter. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-05-18 English
GRANT OF WAIVER FROM STRICT COMPLIANCE WITH RULE 14.41(A) OF THE LISTING RULES
Regulatory Filings Classification · 95% confidence The document is an announcement from Overseas Chinese Town (Asia) Holdings Limited regarding the grant of a waiver from strict compliance with a specific listing rule (Rule 14.41(a)) by the Stock Exchange of Hong Kong. It references previous announcements and the condition to dispatch a Circular to shareholders. The content is regulatory in nature, related to compliance and listing rules, and does not contain financial statements, management discussion, or detailed report data. The document is relatively short (2348 characters) and serves as a formal announcement rather than a full report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-05-18 English
ANNOUNCEMENT REGARDING H SHARE FULL CIRCULATION LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE
Capital/Financing Update Classification · 95% confidence The document is an announcement from RemeGen Co., Ltd. regarding the approval granted by the Stock Exchange for the full circulation listing of H shares. It details the shareholding structure before and after the conversion, the procedures for conversion and trading, and the expected timetable for listing. The document does not contain financial statements or detailed financial performance data but rather informs about a regulatory approval and procedural update related to share listing and trading. It is not a full annual or interim report, earnings release, or management discussion. The document is a formal announcement about a capital market event (listing approval and share conversion). Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is over 10,000 characters, indicating it is not a brief notice or a simple report publication announcement. Hence, the classification is CAP with high confidence.
2021-05-17 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.